Insider · CIK 0001454771
Pol F Boudes
Files at PLX (Protalix BioTherapeutics, Inc.). First filing -, latest -.
Pol F Boudes files SEC Form 4 as director at PLX (Protalix BioTherapeutics, Inc.). No open-market trade is on file; the transactions below are grants, exercises and other rows that carry no view on the price.
A track record needs three past buys with six months of prices behind them; Pol F Boudes has 0, so none is measured yet.
Signals
This insider’s open-market buys and sells, scored.
Transactions
Every row this insider has filed, 4 in all, newest first.
| Date | Company | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Sep 3, 2026 | PLX Protalix BioTherapeutics, Inc. | AGrant or award Stock Options (Right to Buy)derivative | +17,000 | $0.00 | $0 | 17,000 | 39 d ago |
| Sep 3, 2026 | PLX Protalix BioTherapeutics, Inc. | AGrant or award Restricted Stock Unitsderivative | +8,500 | $0.00 | $0 | 8,500 | 39 d ago |
| Sep 3, 2025 | PLX Protalix BioTherapeutics, Inc. | AGrant or award Common Stockindirect: By Trust | +7,500 | - | - | 7,500 | Sep 4, 2025 |
| Sep 3, 2025 | PLX Protalix BioTherapeutics, Inc. | AGrant or award Stock Options (Right to Buy)derivative | +15,000 | $0.00 | $0 | 15,000 | Sep 4, 2025 |
Questions about Pol F Boudes
Answered from the filings on this page, as of the latest one.
Is Pol F Boudes buying or selling?
Pol F Boudes has no open-market buy or sell on SEC Form 4; the filings on record are grants, exercises and other transactions.
How did Pol F Boudes's past buys perform?
Not measured yet. InsiderTell needs three past buys with six months of prices to publish a track record, and Pol F Boudes has 0.
Where does Pol F Boudes file Form 4?
Pol F Boudes has filed Form 4 at PLX (Protalix BioTherapeutics, Inc.). A Form 4 is required of officers, directors and holders of more than 10% of a share class within two business days of a trade.
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.